26 results on '"Stamm, Thomas J."'
Search Results
2. Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder
- Author
-
Reinbold, Céline S, Forstner, Andreas J, Hecker, Julian, Fullerton, Janice M, Hoffmann, Per, Hou, Liping, Heilbronner, Urs, Degenhardt, Franziska, Adli, Mazda, Akiyama, Kazufumi, Akula, Nirmala, Ardau, Raffaella, Arias, Bárbara, Backlund, Lena, Benabarre, Antonio, Bengesser, Susanne, Bhattacharjee, Abesh K, Biernacka, Joanna M, Birner, Armin, Marie-Claire, Cynthia, Cervantes, Pablo, Chen, Guo-Bo, Chen, Hsi-Chung, Chillotti, Caterina, Clark, Scott R, Colom, Francesc, Cousins, David A, Cruceanu, Cristiana, Czerski, Piotr M, Dayer, Alexandre, Étain, Bruno, Falkai, Peter, Frisén, Louise, Gard, Sébastien, Garnham, Julie S, Goes, Fernando S, Grof, Paul, Gruber, Oliver, Hashimoto, Ryota, Hauser, Joanna, Herms, Stefan, Jamain, Stéphane, Jiménez, Esther, Kahn, Jean-Pierre, Kassem, Layla, Kittel-Schneider, Sarah, Kliwicki, Sebastian, König, Barbara, Kusumi, Ichiro, Lackner, Nina, Laje, Gonzalo, Landén, Mikael, Lavebratt, Catharina, Leboyer, Marion, Leckband, Susan G, Jaramillo, Carlos A López, MacQueen, Glenda, Manchia, Mirko, Martinsson, Lina, Mattheisen, Manuel, McCarthy, Michael J, McElroy, Susan L, Mitjans, Marina, Mondimore, Francis M, Monteleone, Palmiero, Nievergelt, Caroline M, Ösby, Urban, Ozaki, Norio, Perlis, Roy H, Pfennig, Andrea, Reich-Erkelenz, Daniela, Rouleau, Guy A, Schofield, Peter R, Schubert, K Oliver, Schweizer, Barbara W, Seemüller, Florian, Severino, Giovanni, Shekhtman, Tatyana, Shilling, Paul D, Shimoda, Kazutaka, Simhandl, Christian, Slaney, Claire M, Smoller, Jordan W, Squassina, Alessio, Stamm, Thomas J, Stopkova, Pavla, Tighe, Sarah K, Tortorella, Alfonso, Turecki, Gustavo, Volkert, Julia, Witt, Stephanie H, Wright, Adam J, Young, L Trevor, Zandi, Peter P, Potash, James B, DePaulo, J Raymond, Bauer, Michael, Reininghaus, Eva, Novák, Tomáš, and Aubry, Jean-Michel
- Subjects
Mental Health ,Brain Disorders ,Clinical Research ,Serious Mental Illness ,Bipolar Disorder ,Human Genome ,Genetics ,Biotechnology ,2.1 Biological and endogenous factors ,Aetiology ,Mental health ,bipolar disorder ,lithium response ,microRNA ,common variants ,genome-wide association study ,Clinical Sciences ,Public Health and Health Services ,Psychology - Abstract
Bipolar disorder (BD) is a common, highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. Lithium is the best-established long-term treatment for BD, even though individual response is highly variable. Evidence suggests that some of this variability has a genetic basis. This is supported by the largest genome-wide association study (GWAS) of lithium response to date conducted by the International Consortium on Lithium Genetics (ConLiGen). Recently, we performed the first genome-wide analysis of the involvement of miRNAs in BD and identified nine BD-associated miRNAs. However, it is unknown whether these miRNAs are also associated with lithium response in BD. In the present study, we therefore tested whether common variants at these nine candidate miRNAs contribute to the variance in lithium response in BD. Furthermore, we systematically analyzed whether any other miRNA in the genome is implicated in the response to lithium. For this purpose, we performed gene-based tests for all known miRNA coding genes in the ConLiGen GWAS dataset (n = 2,563 patients) using a set-based testing approach adapted from the versatile gene-based test for GWAS (VEGAS2). In the candidate approach, miR-499a showed a nominally significant association with lithium response, providing some evidence for involvement in both development and treatment of BD. In the genome-wide miRNA analysis, 71 miRNAs showed nominally significant associations with the dichotomous phenotype and 106 with the continuous trait for treatment response. A total of 15 miRNAs revealed nominal significance in both phenotypes with miR-633 showing the strongest association with the continuous trait (p = 9.80E-04) and miR-607 with the dichotomous phenotype (p = 5.79E-04). No association between miRNAs and treatment response to lithium in BD in either of the tested conditions withstood multiple testing correction. Given the limited power of our study, the investigation of miRNAs in larger GWAS samples of BD and lithium response is warranted.
- Published
- 2018
3. Leptin gene polymorphisms are associated with weight gain during lithium augmentation in patients with major depression
- Author
-
Bopp, Sandra K., Heilbronner, Urs, Schlattmann, Peter, Mühleisen, Thomas W., Bschor, Tom, Richter, Christoph, Steinacher, Bruno, Stamm, Thomas J., Merkl, Angela, Herms, Stefan, Köhler, Stephan, Sterzer, Philipp, Hellweg, Rainer, Heinz, Andreas, Cichon, Sven, Lang, Undine E., Schulze, Thomas G., Adli, Mazda, and Ricken, Roland
- Published
- 2019
- Full Text
- View/download PDF
4. Adjuvant psychotherapy in early-stage bipolar disorder: study protocol for a randomized controlled trial
- Author
-
Stamm, Thomas J., Zwick, Julia C., O’Malley, Grace, Sondergeld, Lene-Marie, and Hautzinger, Martin
- Published
- 2020
- Full Text
- View/download PDF
5. Acute effects of lithium augmentation on the kidney in geriatric compared with non‐geriatric patients with treatment‐resistant depression
- Author
-
Osterland, Sarah Luise, primary, Adli, Mazda, additional, Saritas, Turgay, additional, Schlattmann, Peter, additional, Behr, Joachim, additional, Müller‐Mertel, Ronja, additional, Hoffmann, Kai, additional, Stamm, Thomas J., additional, Bschor, Tom, additional, Richter, Christoph, additional, Steinacher, Bruno, additional, Jockers‐Scherübl, Maria‐Christiane, additional, Köhler, Stephan, additional, Heinz, Andreas, additional, Ricken, Roland, additional, and Buspavanich, Pichit, additional
- Published
- 2023
- Full Text
- View/download PDF
6. The Big Five Model in Bipolar Disorder: A Latent Profile Analysis and its Impact on Longterm Illness Severity
- Author
-
Ortelbach, Niklas, primary, Rote, Jonas, additional, Dingelstadt, Alice Mai Ly, additional, Stolzenburg, Anna, additional, Koenig, Cornelia, additional, O'Malley, Grace, additional, Quinlivan, Esther, additional, Fiebig, Jana, additional, Pfeiffer, Steffi, additional, König, Barbara, additional, Simhandl, Christian, additional, Bauer, Michael, additional, Pfennig, Andrea, additional, and Stamm, Thomas J., additional
- Published
- 2021
- Full Text
- View/download PDF
7. Efficacy of cognitive-behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study
- Author
-
Leopold, Karolina, Bauer, Michael, Bechdolf, Andreas, Correll, Christoph U., Holtmann, Martin, Juckel, Georg, Lambert, Martin, Meyer, Thomas D., Pfeiffer, Steffi, Kittel-Schneider, Sarah, Reif, Andreas, Stamm, Thomas J., Rottmann-Wolf, Maren, Mathiebe, Josephine, Kellmann, Eva L., Ritter, Philipp, Kruger-Ozgurdal, Seza, Karow, Anne, Sondergeld, Lene-Marie, Roessner, Veit, Sauer, Cathrin, Pfennig, Andrea, Leopold, Karolina, Bauer, Michael, Bechdolf, Andreas, Correll, Christoph U., Holtmann, Martin, Juckel, Georg, Lambert, Martin, Meyer, Thomas D., Pfeiffer, Steffi, Kittel-Schneider, Sarah, Reif, Andreas, Stamm, Thomas J., Rottmann-Wolf, Maren, Mathiebe, Josephine, Kellmann, Eva L., Ritter, Philipp, Kruger-Ozgurdal, Seza, Karow, Anne, Sondergeld, Lene-Marie, Roessner, Veit, Sauer, Cathrin, and Pfennig, Andrea
- Abstract
Objective Most patients with bipolar disorders (BD) exhibit prodromal symptoms before a first (hypo)manic episode. Patients with clinically significant symptoms fulfilling at-risk criteria for serious mental illness (SMI) require effective and safe treatment. Cognitive-behavioral psychotherapy (CBT) has shown promising results in early stages of BD and in patients at high risk for psychosis. We aimed to investigate whether group CBT can improve symptoms and functional deficits in young patients at risk for SMI presenting with subthreshold bipolar symptoms. Method In a multicenter, randomized, controlled trial, patients at clinical risk for SMI presenting with subthreshold bipolar symptoms aged 15-30 years were randomized to 14 weeks of at-risk for BD-specific group CBT or unstructured group meetings. Primary efficacy endpoints were differences in affective symptomatology and psychosocial functioning at 14 weeks. At-risk status was defined as a combination of subthreshold bipolar symptomatology, reduction of psychosocial functioning and a family history for (schizo)affective disorders. A prespecified interim analysis was conducted at 75% of the targeted sample. Results Of 128 screened participants, 75 were randomized to group CBT (n = 38, completers = 65.8%) vs unstructured group meetings (n = 37, completers = 78.4%). Affective symptomatology and psychosocial functioning improved significantly at week 14 (P < .001) and during 6 months (P < .001) in both groups, without significant between-group differences. Findings are limited by the interim character of the analysis, the use of not fully validated early detection interviews, a newly adapted intervention manual, and the substantial drop-outs. Conclusions Results suggest that young patients at-risk for SMI presenting with subthreshold bipolar symptoms benefit from early group sessions. The degree of specificity and psychotherapeutic interaction needed requires clarification.
- Published
- 2020
8. Efficacy of cognitive‐behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study
- Author
-
Leopold, Karolina, primary, Bauer, Michael, additional, Bechdolf, Andreas, additional, Correll, Christoph U., additional, Holtmann, Martin, additional, Juckel, Georg, additional, Lambert, Martin, additional, Meyer, Thomas D., additional, Pfeiffer, Steffi, additional, Kittel‐Schneider, Sarah, additional, Reif, Andreas, additional, Stamm, Thomas J., additional, Rottmann‐Wolf, Maren, additional, Mathiebe, Josephine, additional, Kellmann, Eva L., additional, Ritter, Philipp, additional, Krüger‐Özgürdal, Seza, additional, Karow, Anne, additional, Sondergeld, Lene‐Marie, additional, Roessner, Veit, additional, Sauer, Cathrin, additional, and Pfennig, Andrea, additional
- Published
- 2020
- Full Text
- View/download PDF
9. A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients ‐ Results from the German Algorithm Project (GAP3)
- Author
-
Ricken, Roland, Wiethoff, Katja, Reinhold, Thomas, Stamm, Thomas J., Baghai, Thomas C., Fisher, Robert, Seemüller, Florian, Brieger, Peter, Cordes, Joachim, Laux, Gerd, Hauth, Iris, Möller, Hans-Jürgen, Heinz, Andreas, Bauer, Michael, and Adli, Mazda
- Published
- 2018
- Full Text
- View/download PDF
10. Cytokine serum levels remain unchanged during lithium augmentation of antidepressants in major depression
- Author
-
Ricken, Roland, Busche, Marlene, Schlattmann, Peter, Himmerich, Hubertus, Bopp, Sandra, Bschor, Tom, Richter, Christoph, Stamm, Thomas J., Heinz, Andreas, Hellweg, Rainer, Lang, Undine E., and Adli, Mazda
- Published
- 2018
- Full Text
- View/download PDF
11. 2018_Supplement_table_III_ – Supplemental material for Impulsivity predicts illness severity in long-term course of bipolar disorder: A prospective approach
- Author
-
Rote, Jonas, Alice-Mai-Ly Dingelstadt, Aigner, Annette, Bauer, Michael, Fiebig, Jana, König, Barbara, Kunze, Johanna, Pfeiffer, Steffi, Pfennig, Andrea, Quinlivan, Esther, Simhandl, Christian, and Stamm, Thomas J
- Subjects
FOS: Psychology ,FOS: Clinical medicine ,170199 Psychology not elsewhere classified ,110319 Psychiatry (incl. Psychotherapy) ,Neuroscience - Abstract
Supplemental material, 2018_Supplement_table_III_ for Impulsivity predicts illness severity in long-term course of bipolar disorder: A prospective approach by Jonas Rote, Alice-Mai-Ly Dingelstadt, Annette Aigner, Michael Bauer, Jana Fiebig, Barbara König, Johanna Kunze, Steffi Pfeiffer, Andrea Pfennig, Esther Quinlivan, Christian Simhandl and Thomas J Stamm in Australian & New Zealand Journal of Psychiatry
- Published
- 2018
- Full Text
- View/download PDF
12. Leptin serum concentrations are associated with weight gain during lithium augmentation
- Author
-
Ricken, Roland, Bopp, Sandra, Schlattmann, Peter, Himmerich, Hubertus, Bschor, Tom, Richter, Christoph, Stamm, Thomas J., Bauer, Frank, Heinz, Andreas, Hellweg, Rainer, Lang, Undine E., and Adli, Mazda
- Published
- 2016
- Full Text
- View/download PDF
13. Impulsivity predicts illness severity in long-term course of bipolar disorder: A prospective approach
- Author
-
Rote, Jonas, primary, Dingelstadt, Alice-Mai-Ly, additional, Aigner, Annette, additional, Bauer, Michael, additional, Fiebig, Jana, additional, König, Barbara, additional, Kunze, Johanna, additional, Pfeiffer, Steffi, additional, Pfennig, Andrea, additional, Quinlivan, Esther, additional, Simhandl, Christian, additional, and Stamm, Thomas J, additional
- Published
- 2018
- Full Text
- View/download PDF
14. The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression
- Author
-
Stamm, Thomas J., Rampp, Carina, Wiethoff, Katja, Stingl, Julia, Mössner, Rainald, O'Malley, Grace, Ricken, Roland, Seemüller, Florian, Keck, Martin, Fisher, Robert, Gaebel, Wolfgang, Maier, Wolfgang, Möller, Hans-Jürgen, Bauer, Michael, and Adli, Mazda
- Subjects
Depression, algorithm, pharmacogenetics ,Depressionen, Algorithmen, Pharmakogenetik ,ddc:610 - Abstract
Objective: The FKBP5-gene influences the HPA-system by modulating the sensitivity of the glucocorticoid receptor (GR). The polymorphism rs1360780 has been associated with response in studies with heterogeneous antidepressant treatment. In contrast, several antidepressant studies with standardized antidepressant treatment could not detect this effect. We therefore compared patients with standardized vs naturalistic antidepressant treatment to (a) investigate a possible interaction between FKBP5-genotype and treatment mode and (b) replicate the effect of the FKBP5-genotype on antidepressant treatment outcome. Methods: A total of 298 major depressive disorder (MDD) inpatients from the multicentred German project and the Zurich Algorithm Project were genotyped for their FKBP5 status. Patients were treated as usual (n=127) or according to a standardized algorithm (n=171). Main outcome criteria was remission (Hamilton Depression Rating Scale-21
- Published
- 2016
15. Ghrelin Serum Concentrations Are Associated with Treatment Response During Lithium Augmentation of Antidepressants
- Author
-
Ricken, Roland, primary, Bopp, Sandra, additional, Schlattmann, Peter, additional, Himmerich, Hubertus, additional, Bschor, Tom, additional, Richter, Christoph, additional, Elstner, Samuel, additional, Stamm, Thomas J, additional, Schulz-Ratei, Brigitte, additional, Lingesleben, Alexandra, additional, Reischies, Friedel M, additional, Sterzer, Philipp, additional, Borgwardt, Stefan, additional, Bauer, Michael, additional, Heinz, Andreas, additional, Hellweg, Rainer, additional, Lang, Undine E, additional, and Adli, Mazda, additional
- Published
- 2017
- Full Text
- View/download PDF
16. How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial
- Author
-
Adli, Mazda, primary, Wiethoff, Katja, additional, Baghai, Thomas C, additional, Fisher, Robert, additional, Seemüller, Florian, additional, Laakmann, Gregor, additional, Brieger, Peter, additional, Cordes, Joachim, additional, Malevani, Jaroslav, additional, Laux, Gerd, additional, Hauth, Iris, additional, Möller, Hans-Jürgen, additional, Kronmüller, Klaus-Thomas, additional, Smolka, Michael N, additional, Schlattmann, Peter, additional, Berger, Maximilian, additional, Ricken, Roland, additional, Stamm, Thomas J, additional, Heinz, Andreas, additional, and Bauer, Michael, additional
- Published
- 2017
- Full Text
- View/download PDF
17. Autobiographical Memory in Bipolar Disorder and Its Link to Neuropsychological Functioning
- Author
-
Quinlivan, Esther, primary, Dallacker, Mattea, additional, Renneberg, Babette, additional, Strasser, Elisa, additional, Fiebig, Jana, additional, and Stamm, Thomas J., additional
- Published
- 2017
- Full Text
- View/download PDF
18. The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression
- Author
-
Stamm, Thomas J, primary, Rampp, Carina, additional, Wiethoff, Katja, additional, Stingl, Julia, additional, Mössner, Rainald, additional, O′Malley, Grace, additional, Ricken, Roland, additional, Seemüller, Florian, additional, Keck, Martin, additional, Fisher, Robert, additional, Gaebel, Wolfgang, additional, Maier, Wolfgang, additional, Möller, Hans-Jürgen, additional, Bauer, Michael, additional, and Adli, Mazda, additional
- Published
- 2015
- Full Text
- View/download PDF
19. Impulsivity predicts illness severity in long-term course of bipolar disorder: A prospective approach.
- Author
-
Quinlivan, Esther, Rote, Jonas, Dingelstadt, Alice-Mai-Ly, Fiebig, Jana, Stamm, Thomas J., Bauer, Michael, Pfeiffer, Steffi, Pfennig, Andrea, Aigner, Annette, König, Barbara, Kunze, Johanna, and Simhandl, Christian
- Subjects
DIAGNOSIS of bipolar disorder ,AGE factors in disease ,DISEASES ,LONGITUDINAL method ,REGRESSION analysis ,PREDICTIVE tests ,SEVERITY of illness index - Abstract
Background: Bipolar disorder is a common, severe and chronic mental illness. Despite this, predictors of illness severity remain poorly understood. Impulsivity is reported to be associated with bipolar disorder and aggravating comorbidities. This study therefore sought to examine the predictive value of impulsivity for determining illness severity in euthymic bipolar disorder patients. Methods: Baseline trait impulsivity of 120 bipolar euthymic patients (81 bipolar disorder I [68%], 80 female [67%]) and 51 healthy controls was assessed using Barratt Impulsiveness Scale 11. The impact of impulsivity on illness severity (measured with morbidity index) was prospectively tested in 97 patients with sufficient follow-up data (average observation time: 54.4 weeks), using linear regression analysis. Results: Barratt Impulsiveness Scale 11 total (β = 0.01; p < 0.01) and in particular Barratt Impulsiveness Scale 11 attentional subscale scores (β = 0.04; p < 0.001) predicted illness severity in bipolar disorder, while controlling for other clinical variables. Only age at onset persisted as an additional, but less influential predictor. Barratt Impulsiveness Scale 11 total scores and Barratt Impulsiveness Scale 11 attentional subscale scores were significantly higher in euthymic patients compared to controls. This was not observed for the motor or non-planning subscale scores. Limitations: The average year-long observation time might not be long enough to account for the chronic course of bipolar disorder. Conclusion: Trait impulsivity and particularly attentional impulsivity in euthymic bipolar patients can be strong predictors of illness severity in bipolar disorder. Future studies should explore impulsivity as a risk assessment for morbidity and as a therapeutic target in bipolar disorder patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Brain-Derived Neurotrophic Factor Serum Concentrations in Acute Depressive Patients Increase During Lithium Augmentation of Antidepressants
- Author
-
Ricken, Roland, primary, Adli, Mazda, additional, Lange, Claudia, additional, Krusche, Esther, additional, Stamm, Thomas J., additional, Gaus, Sebastian, additional, Koehler, Stephan, additional, Nase, Sarah, additional, Bschor, Tom, additional, Richter, Christoph, additional, Steinacher, Bruno, additional, Heinz, Andreas, additional, Rapp, Michael A., additional, Borgwardt, Stefan, additional, Hellweg, Rainer, additional, and Lang, Undine E., additional
- Published
- 2013
- Full Text
- View/download PDF
21. Supraphysiologic Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression
- Author
-
Stamm, Thomas J., primary, Lewitzka, Ute, additional, Sauer, Cathrin, additional, Pilhatsch, Maximilian, additional, Smolka, Michael N., additional, Koeberle, Ursula, additional, Adli, Mazda, additional, Ricken, Roland, additional, Scherk, Harald, additional, Frye, Mark A., additional, Juckel, Georg, additional, Assion, Hans-Joerg, additional, Gitlin, Michael, additional, Whybrow, Peter C., additional, and Bauer, Michael, additional
- Published
- 2013
- Full Text
- View/download PDF
22. Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder
- Author
-
Reinbold, Céline S., Forstner, Andreas J., Hecker, Julian, Fullerton, Janice M., Hoffmann, Per, Hou, Liping, Heilbronner, Urs, Degenhardt, Franziska, Adli, Mazda, Akiyama, Kazufumi, Akula, Nirmala, Ardau, Raffaella, Arias, Bárbara, Backlund, Lena, Benabarre, Antonio, Bengesser, Susanne, Bhattacharjee, Abesh K., Biernacka, Joanna M., Birner, Armin, Marie-Claire, Cynthia, Cervantes, Pablo, Chen, Guo-Bo, Chen, Hsi-Chung, Chillotti, Caterina, Clark, Scott R., Colom, Francesc, Cousins, David A., Cruceanu, Cristiana, Czerski, Piotr M., Dayer, Alexandre, Étain, Bruno, Falkai, Peter, Frisén, Louise, Gard, Sébastien, Garnham, Julie S., Goes, Fernando S., Grof, Paul, Gruber, Oliver, Hashimoto, Ryota, Hauser, Joanna, Herms, Stefan, Jamain, Stéphane, Jiménez, Esther, Kahn, Jean-Pierre, Kassem, Layla, Kittel-Schneider, Sarah, Kliwicki, Sebastian, König, Barbara, Kusumi, Ichiro, Lackner, Nina, Laje, Gonzalo, Landén, Mikael, Lavebratt, Catharina, Leboyer, Marion, Leckband, Susan G., López Jaramillo, Carlos A., MacQueen, Glenda, Manchia, Mirko, Martinsson, Lina, Mattheisen, Manuel, McCarthy, Michael J., McElroy, Susan L., Mitjans, Marina, Mondimore, Francis M., Monteleone, Palmiero, Nievergelt, Caroline M., Ösby, Urban, Ozaki, Norio, Perlis, Roy H., Pfennig, Andrea, Reich-Erkelenz, Daniela, Rouleau, Guy A., Schofield, Peter R., Schubert, K. Oliver, Schweizer, Barbara W., Seemüller, Florian, Severino, Giovanni, Shekhtman, Tatyana, Shilling, Paul D., Shimoda, Kazutaka, Simhandl, Christian, Slaney, Claire M., Smoller, Jordan W., Squassina, Alessio, Stamm, Thomas J., Stopkova, Pavla, Tighe, Sarah K., Tortorella, Alfonso, Turecki, Gustavo, Volkert, Julia, Witt, Stephanie H., Wright, Adam J., Young, L. Trevor, Zandi, Peter P., Potash, James B., DePaulo, J. Raymond, Bauer, Michael, Reininghaus, Eva, Novák, Tomáš, Aubry, Jean-Michel, Maj, Mario, Baune, Bernhard T., Mitchell, Philip B., Vieta, Eduard, Frye, Mark A., Rybakowski, Janusz K., Kuo, Po-Hsiu, Kato, Tadafumi, Grigoroiu-Serbanescu, Maria, Reif, Andreas, Del Zompo, Maria, Bellivier, Frank, Schalling, Martin, Wray, Naomi R., Kelsoe, John R., Alda, Martin, McMahon, Francis J., Schulze, Thomas G., Rietschel, Marcella, Nöthen, Markus M., and Cichon, Sven
- Subjects
bipolar disorder ,lithium response ,microRNA ,common variants ,genome-wide association study - Abstract
Bipolar disorder (BD) is a common, highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. Lithium is the best-established long-term treatment for BD, even though individual response is highly variable. Evidence suggests that some of this variability has a genetic basis. This is supported by the largest genome-wide association study (GWAS) of lithium response to date conducted by the International Consortium on Lithium Genetics (ConLiGen). Recently, we performed the first genome-wide analysis of the involvement of miRNAs in BD and identified nine BD-associated miRNAs. However, it is unknown whether these miRNAs are also associated with lithium response in BD. In the present study, we therefore tested whether common variants at these nine candidate miRNAs contribute to the variance in lithium response in BD. Furthermore, we systematically analyzed whether any other miRNA in the genome is implicated in the response to lithium. For this purpose, we performed gene-based tests for all known miRNA coding genes in the ConLiGen GWAS dataset (n = 2,563 patients) using a set-based testing approach adapted from the versatile gene-based test for GWAS (VEGAS2). In the candidate approach, miR-499a showed a nominally significant association with lithium response, providing some evidence for involvement in both development and treatment of BD. In the genome-wide miRNA analysis, 71 miRNAs showed nominally significant associations with the dichotomous phenotype and 106 with the continuous trait for treatment response. A total of 15 miRNAs revealed nominal significance in both phenotypes with miR-633 showing the strongest association with the continuous trait (p = 9.80E-04) and miR-607 with the dichotomous phenotype (p = 5.79E-04). No association between miRNAs and treatment response to lithium in BD in either of the tested conditions withstood multiple testing correction. Given the limited power of our study, the investigation of miRNAs in larger GWAS samples of BD and lithium response is warranted.
- Published
- 2018
- Full Text
- View/download PDF
23. Serotonin transporter gene and response to lithium augmentation in depression
- Author
-
Stamm, Thomas J., primary, Adli, Mazda, additional, Kirchheiner, Julia, additional, Smolka, Michael N., additional, Kaiser, Rolf, additional, Tremblay, Pierre Benoit, additional, and Bauer, Michael, additional
- Published
- 2008
- Full Text
- View/download PDF
24. Supraphysiologic Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression: A Randomized, Double-Blind, Placebo-Controlled Study.
- Author
-
Stamm, Thomas J., Lewitzka, Ute, Sauer, Cathrin, Pilhatsch, Maximilian, Smolka, Michael N., Koeberle, Ursula, Adli, Mazda, Ricken, Roland, Scherk, Harald, Frye, Mark A., Juckel, Georg, Assion, Hans-Joerg, Gitlin, Michael, Whybrow, Peter C., and Bauer, Michael
- Published
- 2014
- Full Text
- View/download PDF
25. Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder
- Author
-
Céline S. Reinbold, Andreas J. Forstner, Julian Hecker, Janice M. Fullerton, Per Hoffmann, Liping Hou, Urs Heilbronner, Franziska Degenhardt, Mazda Adli, Kazufumi Akiyama, Nirmala Akula, Raffaella Ardau, Bárbara Arias, Lena Backlund, Antonio Benabarre, Susanne Bengesser, Abesh K. Bhattacharjee, Joanna M. Biernacka, Armin Birner, Cynthia Marie-Claire, Pablo Cervantes, Guo-Bo Chen, Hsi-Chung Chen, Caterina Chillotti, Scott R. Clark, Francesc Colom, David A. Cousins, Cristiana Cruceanu, Piotr M. Czerski, Alexandre Dayer, Bruno Étain, Peter Falkai, Louise Frisén, Sébastien Gard, Julie S. Garnham, Fernando S. Goes, Paul Grof, Oliver Gruber, Ryota Hashimoto, Joanna Hauser, Stefan Herms, Stéphane Jamain, Esther Jiménez, Jean-Pierre Kahn, Layla Kassem, Sarah Kittel-Schneider, Sebastian Kliwicki, Barbara König, Ichiro Kusumi, Nina Lackner, Gonzalo Laje, Mikael Landén, Catharina Lavebratt, Marion Leboyer, Susan G. Leckband, Carlos A. López Jaramillo, Glenda MacQueen, Mirko Manchia, Lina Martinsson, Manuel Mattheisen, Michael J. McCarthy, Susan L. McElroy, Marina Mitjans, Francis M. Mondimore, Palmiero Monteleone, Caroline M. Nievergelt, Urban Ösby, Norio Ozaki, Roy H. Perlis, Andrea Pfennig, Daniela Reich-Erkelenz, Guy A. Rouleau, Peter R. Schofield, K. Oliver Schubert, Barbara W. Schweizer, Florian Seemüller, Giovanni Severino, Tatyana Shekhtman, Paul D. Shilling, Kazutaka Shimoda, Christian Simhandl, Claire M. Slaney, Jordan W. Smoller, Alessio Squassina, Thomas J. Stamm, Pavla Stopkova, Sarah K. Tighe, Alfonso Tortorella, Gustavo Turecki, Julia Volkert, Stephanie H. Witt, Adam J. Wright, L. Trevor Young, Peter P. Zandi, James B. Potash, J. Raymond DePaulo, Michael Bauer, Eva Reininghaus, Tomáš Novák, Jean-Michel Aubry, Mario Maj, Bernhard T. Baune, Philip B. Mitchell, Eduard Vieta, Mark A. Frye, Janusz K. Rybakowski, Po-Hsiu Kuo, Tadafumi Kato, Maria Grigoroiu-Serbanescu, Andreas Reif, Maria Del Zompo, Frank Bellivier, Martin Schalling, Naomi R. Wray, John R. Kelsoe, Martin Alda, Francis J. McMahon, Thomas G. Schulze, Marcella Rietschel, Markus M. Nöthen, Sven Cichon, University Hospital Basel [Basel], Universitätsklinikum Bonn (UKB), Neuroscience Research Australia (NeuRA), Translational Centre for Regenerative Medicine (TRM), Department of Cell Therapy, Universität Leipzig [Leipzig]-Universität Leipzig [Leipzig], Human Genetics Branch, National Institutes of Health [Bethesda] (NIH)-National Institute of Mental Health (NIMH), Department of Psychiatry and Psychotherapy, Georg-August-University [Göttingen], Department of Genomics, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Unit of Clinical Pharmacology, University-Hospital of Cagliari, Department of Psychiatry, Trinity College Dublin-St. James's Hospital, Mayo Clinic, University of Adelaide, McGill University = Université McGill [Montréal, Canada], Psychiatric Genetic Unit, Poznan University of Medical Sciences, Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Sorbonne Paris Cité (USPC), Université Paris Diderot - Paris 7 (UPD7), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Homburg, Department of Molecular Medicine, Karolinska Institutet [Stockholm], Service de psychiatrie adulte, Université Bordeaux Segalen - Bordeaux 2-Hôpital Charles Perrens, Dalhousie University [Halifax], Johns Hopkins University (JHU), Mood Disorders Center of Ottawa (MDCO), University of Ottawa [Ottawa], Department of Psychiatry [Heidelberg], University of Heidelberg, Medical Faculty, Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University [Osaka], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IrsiCaixa (Institut de Recerca de la Sida), Service de Psychiatrie et Psychologie Clinique, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Hôpital Jeanne-d'Arc, Mental Health Sciences Unit, University College of London [London] (UCL), Department of Adult Psychiatry, Abteilung Informatik und angewandte Kognitionswissenschaft [Duisburg] (INKO), Universität Duisburg-Essen [Essen], Hokkaido University Graduate School of Medicine, Department of medicine [Stockholm], Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm], Molecular Medicine and Surgery department, University of California [San Diego] (UC San Diego), University of California-University of California, University of Antioquia, Università degli Studi di Salerno (UNISA), Department of Clinical Neuroscience, R&D Unit, Department of Psychiatry, Danderyd University Hospital–Karolinska Institutet, Fujita Health University School of Medicine, Center for Human Genetic Research, Harvard Medical School [Boston] (HMS)-Massachusetts General Hospital [Boston], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Prince of Wales Medical Research Institute, University of New South Wales [Sydney] (UNSW), Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Massachusetts General Hospital [Boston], Prague Psychiatric Center, University of Prague, Università degli Studi di Perugia (UNIPG), Department of Psychiatry [Montréal], School of Psychiatry, Black Dog Institute-University of New South Wales [Sydney] (UNSW), Department of Mental Health, Johns Hopkins University and Hospital, Center for Sepsis Control & Care, Jena University Hospital, Medical University Graz, Department of Mental Health and Psychiatry, University Hospital of Geneva, Università degli studi della Campania 'Luigi Vanvitelli', Institute of Neuroscience, Hospital Clinic-IDIBAPS - CIBERSAM - ENBREC-University of Barcelona, Institute of Epidemiology and Preventive Medicine, National Taiwan University [Taiwan] (NTU), Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science [Wako] (RIKEN CBS), RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN)-RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Psychiatric Hospital, Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, King‘s College London, Univerity of Mannheim, Institute of Human Genetics [Erlangen, Allemagne], Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, McGill University, Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), University of Ottawa [Ottawa] (uOttawa), Technische Universität Dresden (TUD), University of New South Wales [Sydney] (UNSW)-Black Dog Institute, RIKEN Brain Science Institute, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Friedrich Alexander University [Erlangen-Nürnberg], Universitat de Barcelona, Georg-August-University = Georg-August-Universität Göttingen, University of California (UC)-University of California (UC), Università degli Studi di Salerno = University of Salerno (UNISA), Danderyds sjukhus = Danderyd University Hospital, Università degli Studi di Perugia = University of Perugia (UNIPG), Università degli studi della Campania 'Luigi Vanvitelli' = University of the Study of Campania Luigi Vanvitelli, Reinbold, Céline S., Forstner, Andreas J., Hecker, Julian, Fullerton, Janice M., Hoffmann, Per, Hou, Liping, Heilbronner, Ur, Degenhardt, Franziska, Adli, Mazda, Akiyama, Kazufumi, Akula, Nirmala, Ardau, Raffaella, Arias, Bárbara, Backlund, Lena, Benabarre, Antonio, Bengesser, Susanne, Bhattacharjee, Abesh K., Biernacka, Joanna M., Birner, Armin, Marie-Claire, Cynthia, Cervantes, Pablo, Chen, Guo-Bo, Chen, Hsi-Chung, Chillotti, Caterina, Clark, Scott R., Colom, Francesc, Cousins, David A., Cruceanu, Cristiana, Czerski, Piotr M., Dayer, Alexandre, Étain, Bruno, Falkai, Peter, Frisén, Louise, Gard, Sébastien, Garnham, Julie S., Goes, Fernando S., Grof, Paul, Gruber, Oliver, Hashimoto, Ryota, Hauser, Joanna, Herms, Stefan, Jamain, Stéphane, Jiménez, Esther, Kahn, Jean-Pierre, Kassem, Layla, Kittel-Schneider, Sarah, Kliwicki, Sebastian, König, Barbara, Kusumi, Ichiro, Lackner, Nina, Laje, Gonzalo, Landén, Mikael, Lavebratt, Catharina, Leboyer, Marion, Leckband, Susan G., Jaramillo, Carlos A. López, Macqueen, Glenda, Manchia, Mirko, Martinsson, Lina, Mattheisen, Manuel, Mccarthy, Michael J., Mcelroy, Susan L., Mitjans, Marina, Mondimore, Francis M., Monteleone, Palmiero, Nievergelt, Caroline M., Ösby, Urban, Ozaki, Norio, Perlis, Roy H., Pfennig, Andrea, Reich-Erkelenz, Daniela, Rouleau, Guy A., Schofield, Peter R., Schubert, K. Oliver, Schweizer, Barbara W., Seemüller, Florian, Severino, Giovanni, Shekhtman, Tatyana, Shilling, Paul D., Shimoda, Kazutaka, Simhandl, Christian, Slaney, Claire M., Smoller, Jordan W., Squassina, Alessio, Stamm, Thomas J., Stopkova, Pavla, Tighe, Sarah K., Tortorella, Alfonso, Turecki, Gustavo, Volkert, Julia, Witt, Stephanie H., Wright, Adam J., Trevor Young, L., Zandi, Peter P., Potash, James B., Depaulo, J. Raymond, Bauer, Michael, Reininghaus, Eva, Novák, Tomáš, Aubry, Jean-Michel, Maj, Mario, Baune, Bernhard T., Mitchell, Philip B., Vieta, Eduard, Frye, Mark A., Rybakowski, Janusz K., Kuo, Po-Hsiu, Kato, Tadafumi, Grigoroiu-Serbanescu, Maria, Reif, Andrea, Zompo, Maria Del, Bellivier, Frank, Schalling, Martin, Wray, Naomi R., Kelsoe, John R., Alda, Martin, Mcmahon, Francis J., Schulze, Thomas G., Rietschel, Marcella, Nöthen, Markus M., and Cichon, Sven
- Subjects
0301 basic medicine ,Genome-wide association study ,Lithium (medication) ,lcsh:RC435-571 ,Bipolar disorder ,Common variants ,Lithium response ,MicroRNA ,Psychiatry and Mental Health ,Common variant ,Lithium ,Biology ,ddc:616.89 ,03 medical and health sciences ,lcsh:Psychiatry ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,common variants ,medicine ,Manic-depressive illness ,ddc:610 ,Gene ,ComputingMilieux_MISCELLANEOUS ,Trastorno Bipolar ,Original Research ,Psychiatry ,bipolar disorder ,Genetics ,MicroARNs ,Trastorn bipolar ,genome-wide association study ,microRNA ,medicine.disease ,genome-wide association stud ,Liti ,Phenotype ,3. Good health ,MicroRNAs ,Psychiatry and Mental health ,030104 developmental biology ,Schizophrenia ,Multiple comparisons problem ,Litio ,medicine.symptom ,Mania ,lithium response ,medicine.drug - Abstract
Bipolar disorder (BD) is a common, highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. Lithium is the best-established long-term treatment for BD, even though individual response is highly variable. Evidence suggests that some of this variability has a genetic basis. This is supported by the largest genome-wide association study (GWAS) of lithium response to date conducted by the International Consortium on Lithium Genetics (ConLiGen). Recently, we performed the first genome-wide analysis of the involvement of miRNAs in BD and identified nine BD-associated miRNAs. However, it is unknown whether these miRNAs are also associated with lithium response in BD. In the present study, we therefore tested whether common variants at these nine candidate miRNAs contribute to the variance in lithium response in BD. Furthermore, we systematically analyzed whether any other miRNA in the genome is implicated in the response to lithium. For this purpose, we performed gene-based tests for all known miRNA coding genes in the ConLiGenGWAS dataset (n = 2,563 patients) using a set-based testing approach adapted from the versatile gene-based test for GWAS (VEGAS2). In the candidate approach, miR-499a showed a nominally significant association with lithium response, providing some evidence for involvement in both development and treatment of BD. In the genomewide miRNA analysis, 71 miRNAs showed nominally significant associations with the dichotomous phenotype and 106 with the continuous trait for treatment response. A total of 15 miRNAs revealed nominal significance in both phenotypes with miR-633 showing the strongest association with the continuous trait (p = 9.80E-04) and miR-607 with the dichotomous phenotype (p = 5.79E-04). No association between miRNAs and treatment response to lithium in BD in either of the tested conditions withstood multiple testing correction. Given the limited power of our study, the investigation of miRNAs in larger GWAS samples of BD and lithium response is warranted. COL0029147
- Published
- 2018
26. The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression.
- Author
-
Stamm TJ, Rampp C, Wiethoff K, Stingl J, Mössner R, O Malley G, Ricken R, Seemüller F, Keck M, Fisher R, Gaebel W, Maier W, Möller HJ, Bauer M, and Adli M
- Subjects
- Adult, Algorithms, Alleles, Depressive Disorder, Major genetics, Depressive Disorder, Major physiopathology, Female, Genotype, Germany, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Psychiatric Status Rating Scales, Remission Induction, Treatment Outcome, Antidepressive Agents therapeutic use, Depressive Disorder, Major drug therapy, Tacrolimus Binding Proteins genetics
- Abstract
Objective: The FKBP5-gene influences the HPA-system by modulating the sensitivity of the glucocorticoid receptor (GR). The polymorphism rs1360780 has been associated with response in studies with heterogeneous antidepressant treatment. In contrast, several antidepressant studies with standardized antidepressant treatment could not detect this effect. We therefore compared patients with standardized vs naturalistic antidepressant treatment to (a) investigate a possible interaction between FKBP5-genotype and treatment mode and (b) replicate the effect of the FKBP5-genotype on antidepressant treatment outcome., Methods: A total of 298 major depressive disorder (MDD) inpatients from the multicentred German project and the Zurich Algorithm Project were genotyped for their FKBP5 status. Patients were treated as usual (n=127) or according to a standardized algorithm (n=171). Main outcome criteria was remission (Hamilton Depression Rating Scale-21<10)., Results: We detected an interaction of treatment as usual (TAU) treatment and C-allele with the worst outcome for patients combining those two factors (HR=0.46; p=0.000). Even though C-allele patients did better when treated in the structured, stepwise treatment algorithm (SSTR) group, we still could confirm the influence of the FKBP5-genotype in the whole sample (HR=0.52; p=0.01)., Conclusions: This is the first study to show an interaction between a genetic polymorphism and treatment mode. Patients with the C-allele of the rs1360780 polymorphism seem to benefit from a standardized antidepressant treatment., (© The Author(s) 2015.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.